Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Roche’s Top-Selling Cancer Drug Approved in Faster Injection Form

By Joanne Van Zuidam | June 23, 2017

The U.S. Food and Drug Administration (FDA) approved Rituxan Hycela for subcutaneous injection.

According to the company, this new treatment includes the same monoclonal antibody as intravenous rituximab (Rituxan) in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin.

The new formulation can be administered in five to seven minutes via injection versus 90 minutes or longer with intravenous infusion. 

The FDA approval is for the treatment of adults with three blood cancers: previously untreated or relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously treated chronic lymphocytic leukemia (CLL).

 “With today’s approval of Rituxan Hycela, people with three of the most common blood cancers now have a new treatment option which provides efficacy comparable with intravenous Rituxan and can be delivered under the skin in minutes instead of hours through IV infusion,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development in a statement.

“People who benefit from Rituxan may receive years of repeated treatments for their blood cancer, so an option that reduces the administration time can be important,” said Horning.

Clinical studies that consisted of nearly 2,000 people have shown that subcutaneous administration of Rituxan Hycela resulted in comparable clinical efficacy outcomes compared to intravenous Rituxan.

Patients can only receive the injection after at least one full dose of intravenous Rituxan.

Studies also showed that adverse reactions were comparable to intravenous rituximab: infections, low white blood cell count (neutropenia), nausea, constipation, cough and fatigue in patients with follicular lymphoma; infections, neutropenia, hair loss, nausea and low red blood cell count in patients with diffuse large B-cell lymphoma; and infections, neutropenia, nausea, low platelet count (thrombocytopenia), fever (pyrexia), vomiting and reddening of the skin (erythema) at the injection site in patients with CLL.

Rituxan Hycela will be available to people in the United States within one to two weeks, and intravenous Rituxan will continue to be available.


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50